Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Cardiovascular/Mitral Regurgitation

Mitral Regurgitation

16

Pipeline Programs↗

36

Active Trials↗

27

Companies Involved↗

Mitral regurgitation is an emerging landscape with 16 programs across 27 companies.

Intelligence

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

47/100

Mech. Concentration

14/100

Completion Rate

61/100

Attrition Rate

12/100

Pipeline

Programs by Phase

Preclinical14

Aspirin

Bayer

Spironolactone

Pfizer

Sacubitril/valsartan

Novartis

Captopril

Standard Chem. & Pharm. Co., Ltd.

Clopidogrel

Sanofi

Phase 1

No programs

Phase 22

Cyproheptadine

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Mydfrin

Montefiore Medical Center

Phase 3

No programs

Approved

No programs

Analysis

Trial Status

58

clinical trials

Recruiting19 · 33%

Completed11 · 19%

Not yet recruiting8 · 14%

Active, not recruiting8 · 14%

Terminated4 · 7%

Unknown status4 · 7%

Other4 · 7%

Clinical Trials

Trial Activity

58 trials

Achieving Optimal Medical Therapy Through Percutaneous Treatment of Secondary Mitral Regurgitation to Improve Outcome in Patients With HFrEF

Recruiting·University Medical Center Mainz·Preclinical·NCT07758023·520 enrolled

Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR Transfemoral System in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial

Recruiting·—·Preclinical·NCT05496998·400 enrolled

Effectiveness and Safety of Edge-to-edge MItral vaLve Repair in Patients With Significant mitraL rEgurgitatioN aNd cardIac ATTR amyLoidosis

Recruiting·MMedical University of Vienna·Preclinical·NCT06075823·106 enrolled

Bio Refine for Functional Mitral Regurgitation - a Safety & Feasibility Study

Recruiting·BBio Refine Ltd.·Preclinical·NCT06583876·15 enrolled

A Clinical Study Evaluating the Replacement of the Native Mitral Valve Using the ReValve System

Recruiting·RReValve Solutions Inc.·Phase 1·NCT07450911·20 enrolled

Cephea Early Feasibility Study

Recruiting·AAbbott Medical Devices·Preclinical·NCT05061004·90 enrolled

Safety and Efficacy of Transcatheter Edge-to-Edge Repair for Atrial Functional Mitral Regurgitation - The STAR Trial

Recruiting·BBeijing Anzhen Hospital·Preclinical·NCT07414225·400 enrolled

Abbott Cephea Mitral Valve Disease Registry

Recruiting·AAbbott Medical Devices·N/A·NCT07069673·1,000 enrolled

Early Feasibility Experience of Posterior Leaflet Replacement to Reduce Mitral Regurgitation Using the MRace Implant (United States)

Recruiting·PPolares Medical SA·Preclinical·NCT07517588·15 enrolled

Capstan Medical TMVR Study: First-in-Human Evaluation of the Capstan TMVR System

Recruiting·CCapstan Medical·Preclinical·NCT06600191·10 enrolled

Effects of VALsartan On atRIAl Mitral Regurgitation: A Pilot Randomized Controlled Trial

Recruiting·—·Preclinical·NCT07539298·50 enrolled

A First-in-Human Investigational Testing Authorization Study Evaluating the Safety and Performance of the Vesalius Transcatheter Mitral Valve Repair System in Patients With Severe, Symptomatic Degenerative Mitral Regurgitation

Recruiting·VVesalius Cardiovascular Inc.·Preclinical·NCT07470788·5 enrolled

Reduction or Elimination of Mitral Regurgitation With the SATURN Trans-septal TMVR System in Patients With Severe, Symptomatic Mitral Regurgitation (Cassini-US)

Recruiting·IInnovHeart·Preclinical·NCT07130994·15 enrolled

ATLAS (A Transseptal Left Atrial System for Treatment of Mitral Regurgitation) Pivotal Trial

Recruiting·44C Medical Technologies, Inc.·Preclinical·NCT06465745·450 enrolled

ENHANCE EFS: Early Feasibility Study (EFS) of the Nyra Cardiac Leaflet Enhancer (CARLEN) System

Recruiting·NNyra Medical, Inc.·Preclinical·NCT07503236·30 enrolled

Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)